Zhongshan Hospital (Xiamen), Fudan University
12
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity
Role: lead
Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial
Role: lead
Epidemiological Studies and Risk Factor Analysis of GERD in Xiamen City
Role: lead
Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)
Role: collaborator
Individualized PEEP Titration on Postoperative Pulmonary Complications
Role: collaborator
Establishment of Diagnosis and Classification System for Lung Interstitial and Airway Diseases (LIAD)
Role: collaborator
The Effects of High-dose Dual Therapy With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment
Role: lead
Predicting Adverse Kidney Events of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers
Role: collaborator
Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy
Role: lead
Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer
Role: lead
Surgery for Masaoka-Koga I-II Thymoma
Role: collaborator
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
Role: collaborator
All 12 trials loaded